Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575
Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.
Stocks · News reference
Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447
Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $447.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462
RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.
Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Raises Price Target to $362
Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and raises the price target from $323 to $362.
Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $582
Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $575 to $582.